Document is current
Any future updates will be listed below
-
Authors
Mortensen, Camilla Bekker https://orcid.org/0000-0001-5202-3552
Andersen-Ranberg, Nina Christine https://orcid.org/0000-0002-0804-1064
Poulsen, Lone Musaeus
Granholm, Anders https://orcid.org/0000-0001-5799-7655
Rasmussen, Bodil Steen https://orcid.org/0000-0003-2190-145X
Kjær, Maj-Brit Nørregaard https://orcid.org/0000-0002-6536-0504
Lange, Theis
Ebdrup, Bjørn H. https://orcid.org/0000-0002-2590-5055
Collet, Marie Oxenbøll
Andreasen, Anne Sofie https://orcid.org/0000-0002-8759-3405
Bestle, Morten Heiberg https://orcid.org/0000-0001-6585-2659
Uslu, Bülent
Pedersen, Helle Scharling
Nielsen, Louise Gramstrup
Hästbacka, Johanna https://orcid.org/0000-0002-3613-7231
Jensen, Troels Bek
Damgaard, Kjeld
Sommer, Trine
Morgen, Matthew
Dey, Nilanjan https://orcid.org/0000-0002-8283-2614
Citerio, Guiseppe
Estrup, Stine https://orcid.org/0000-0002-1467-7085
Egerod, Ingrid https://orcid.org/0000-0002-9576-4390
Samuelson, Karin
Perner, Anders
Mathiesen, Ole https://orcid.org/0000-0003-4544-0619
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03392376 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term outcomes with haloperidol versus placebo in acutely admitted adult ICU patients with delirium
https://doi.org/10.1007/s00134-023-07282-7
Pharmacological interventions for prevention and management of delirium in intensive care patients: a systematic overview of reviews and meta-analyses
https://doi.org/10.1136/bmjopen-2018-024562
-
Funding
Funding for this research was provided by:
Innovationsfonden (4108-00011B)
Region Sjælland
Lund University
- License Information
-
More Information
Article History
Received: 22 September 2023
Accepted: 16 November 2023
First Online: 3 January 2024
Declarations
:
: AG, MBNK, MOC and AP are affiliated with the Department of Intensive Care at Rigshospitalet, which has received funding for other projects from The Novo Nordisk Foundation, Pfizer, and Fresenius Kabi, Sygeforsikringen “danmark”. AP has received an honorarium from Novartis for the participation in an advisory board. AP is on DSMB for The Mega-Rox trial, UK-Rox trial, Bone Zone trial. BSR are affiliated with the Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark, which has received funding for other project from Novo Nordisk Foundation, Danish Ministry of Education and Science and Beckett Foundation. MHB are affiliated with the Department of Anaesthesia and Intensive Care at Copenhagen University Hospital – North Zealand, which has received funding for other research projects from The Novo Nordisk Foundation, Sygeforsikringen “danmark”, Toyota Foundation, A.P. Moeller Foundation, Frimodt-Heineke Foundation, Svend Andersen Foundation, Ehrenreich Foundation, and Olga Bryde Nielsen Foundation, and has conducted contract research for AM-Pharma (the REVIVAL trial) and Inotrem (ASTONISH trial). MHB has received an honorarium from AM-Pharma for participation in an advisory board. TL is a member of DSMB for Novo Nordisk and Leo Pharma study. BE is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S. JH has received funding from Paulo foundation, Finska Läkaresällskapet, NordForsk and Tor och Kirsti Johanssons Hjärt och Cancerstiftelse. GC has received istituational research grants from Neuroptics and Integra and is a board member at Neuroptics, Integra, Biogen, Invex Therapeutics and Idorsia. All other authors have no conflicts to disclose.
